At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 190 enrolled
Drug / intervention
IGE-1 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double Blinded, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Pharmacodynamic Response Of Ascending Dose Levels Of An Anti-ige Vaccine With Two Different Adjuvant Formulations (Pf-06444753 And Pf-06444752) In Generally Healthy Subjects With Allergic Rhinitis
In Brief
A Phase 1 clinical trial evaluating IGE-1, IGE-2, and 1 other intervention for Allergic Rhinitis. Completed, enrolled 190 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of different doses of PF-06444753 and PF-06444752 in subjects with allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartDec 2012
Primary CompletionJun 2015
TodayJul 2026
First PostedNov 7, 2012
Enrollment StartDec 1, 2012
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.7 years ago
Interventions
IGE-1biological
Intramuscular, multiple dose
IGE-2biological
Intramuscular, multiple dose
Salinebiological
Saline (0.9% sodium chloride)